Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
McKesson
Daiichi Sankyo
Healthtrust
Accenture
Fish and Richardson
AstraZeneca
Federal Trade Commission

Generated: July 16, 2018

DrugPatentWatch Database Preview

Cetyl alcohol; colfosceril palmitate; tyloxapol - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for cetyl alcohol; colfosceril palmitate; tyloxapol and what is the scope of cetyl alcohol; colfosceril palmitate; tyloxapol patent protection?

Cetyl alcohol; colfosceril palmitate; tyloxapol
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are ninety-one drug master file entries for cetyl alcohol; colfosceril palmitate; tyloxapol.
Summary for cetyl alcohol; colfosceril palmitate; tyloxapol
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 91
DailyMed Link:cetyl alcohol; colfosceril palmitate; tyloxapol at DailyMed

US Patents and Regulatory Information for cetyl alcohol; colfosceril palmitate; tyloxapol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline EXOSURF NEONATAL cetyl alcohol; colfosceril palmitate; tyloxapol FOR SUSPENSION;INTRATRACHEAL 020044-001 Aug 2, 1990 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for cetyl alcohol; colfosceril palmitate; tyloxapol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline EXOSURF NEONATAL cetyl alcohol; colfosceril palmitate; tyloxapol FOR SUSPENSION;INTRATRACHEAL 020044-001 Aug 2, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline EXOSURF NEONATAL cetyl alcohol; colfosceril palmitate; tyloxapol FOR SUSPENSION;INTRATRACHEAL 020044-001 Aug 2, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline EXOSURF NEONATAL cetyl alcohol; colfosceril palmitate; tyloxapol FOR SUSPENSION;INTRATRACHEAL 020044-001 Aug 2, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Merck
Moodys
Dow
Chubb
McKinsey
US Department of Justice
Teva
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.